- Describe your topic.
- What is the comparative effectiveness and safety of long-term azithormycin therapy versus various other biologics (e.g., omalizumab, mepolizumab, reslizumab, benralizumab, and dupilumab) for the prevention of asthma exacerbations in patients with severe asthma?
- Describe why this topic is important.
- Explore this modality of therapy.
- Tell us why you are suggesting this topic.
- To inform our clinical practice guidelines
- Target Date.
- 2019-11-10
- Describe what you are doing currently and what you are hoping will change because of a new evidence report.
- We are in the process of updating our clinical practice guidelines; this evidence review may inform future recommendations on this type of therapy.
- How will you or your group use the information from a new evidence report?
- Inform clinical practice guidelines
- How would you or your group plan to disseminate information from the report? Who would you plan to disseminate it to?
- Electronic dissemination of our clinical practice guidelines within our program nationally
- Do you know of organizations that could use an evidence report to change clinical practice? Are you a part of, or have you been in contact with, any organizations that might implement the research findings of an evidence report?
- Health care organizations and delivery systems
- Information About You: (optional)
-
- Provide a description of your role or perspective.
- Guideline developer
- If you are you making a suggestion on behalf of an organization, please state the name of the organization.
- Kaiser Permanente Care Management Institute
- Please tell us how you heard about the Effective Health Care Program.
- Colleagues
